MOTS-c dosage and evidence

What is MOTS-c?

How does MOTS-c work?

In animals, under stress MOTS-c moves into the cell's control center and changes which genes are switched on. Part of how it does that is by slowing the folate cycle and the making of purines, building blocks for DNA. That switches on AMPK, an energy sensor, which changes how muscle handles sugar and fat. No receptor has been found. The FDA's 2026 review notes that nobody knows exactly what it acts on, so nobody can predict which organs a shot of MOTS-c would affect. In a dish, MOTS-c mixed with human blood broke down fast into smaller pieces. So it is not clear a shot under the skin could keep enough of it working in the body.

What have studies in people found about MOTS-c?

Nobody has published a study giving MOTS-c to people as a drug. The one registered study is signing people up and has not reported. What exists instead: a gene variant studied in tens of thousands of people, blood levels measured against age, illness and exercise in several hundred more, and the FDA's July 2026 review, which found no data at all on people given compounded MOTS-c.

• Genetics, three Japanese population studies pooled, 27,527 people (Zempo, Fuku and others, 2021): the m.1382A>C variant, found only in Northeast Asia, makes a weaker form of MOTS-c. Men who carried it had more type 2 diabetes, especially men who did not exercise. That is the opposite of an earlier idea that the variant explained long life in East Asia.
• Genetics, people aged 100 or more, 736 studied out of 743 signed up (same 2021 study): the variant was no more common in Japanese people aged 100 or more than in others (7.7% against 7.5%). This tested, and did not back up, a 2015 idea paper that had guessed at a link to long life from a 96-person study.
• Blood levels and metabolic syndrome, 125 Chinese adults plus 34 more women (Sequeira and others, 2021): MOTS-c in the blood was higher, not lower, in people with metabolic syndrome. It rose with belly fat and liver fat. That is the reverse of the heart and child studies below.
• Exercise, 75 pro athletes against 30 people who do not train (Alser and others, 2022): the pro endurance athletes had less MOTS-c in their blood at rest. That goes against a simple 'exercise raises it' story. A separate 2021 paper reports that one bout of exercise raises MOTS-c in human muscle and blood.
• Blood levels and age, 104 healthy men aged 18 to 81 (D'Souza and others, 2020): MOTS-c in the blood was 11% lower in middle-aged men and 21% lower in older men than in young men. In muscle it went the other way, about 1.5 times higher in the older groups.
• Blood levels and child obesity, 40 obese children and teens against 57 of normal weight in China (Du and others, 2018): MOTS-c was lower in obese boys, and the lower it was, the worse their insulin markers. Girls showed no clear difference.
• Blood levels and heart arteries, 40 patients having their heart arteries imaged (Qin and others, 2018): MOTS-c was lower in the 20 whose artery linings worked poorly than in the 20 whose linings worked normally. It tracked how well the heart arteries responded to a test drug.
• Exercise, 30 adults assigned to endurance exercise, weight training or rest (von Walden and others, 2021): humanin in the blood clearly rose after one endurance session. MOTS-c only leaned upward, not enough to count as a real change.
• Signing people up now: NCT07505745 will give 120 adults with prediabetes and extra weight a daily shot under the skin of MOTS-c or a dummy for 12 weeks, plus lifestyle advice. Nobody will know who got which. It measures how well the body handles a sugar drink at week 12. It is expected to finish in February 2027.

What this does not tell you: None of this shows that a MOTS-c shot does anything. A gene variant that makes your own MOTS-c weaker is not the same test as injecting more of it, and the one study that tests that directly has not reported. The blood level studies only watched people. They cannot show cause and effect, and they do not even agree on direction. MOTS-c reads low in heart artery disease and child obesity, but high in metabolic syndrome and liver fat. That suggests it acts differently in different tissues and illnesses. It is not a simple 'more is better' marker. The FDA's 2026 review found no published safety data or blood level data for compounded MOTS-c in people by any route. In the FDA's own lab work, the peptide broke down fast in human blood. So nobody has shown that a shot under the skin even reaches the body in a working form.

What do people who took MOTS-c report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Doses talked about online are mostly 1 to 10 mg a week as a shot under the skin, often split into 2 or 3 shots. Beginner guides suggest 2.5 to 5 mg once or twice a week, then working up. One moderator on a peptide forum described 1 to 2 mg a day. These numbers come from seller and user dosing guides, not from any published study in people. No such study exists for the ways people take it.
• What people describe most is more energy and a sharper mind in the first one to two weeks. Some say it is strong enough that you should not take it near bedtime. People also expect better endurance and body shape when they pair it with training and eating less. Several sources say plainly that MOTS-c is not a fat burner on its own. People who do not also diet or train report no visible change in body shape.
• MOTS-c is often taken as part of a stack, not alone. Common partners are Semax, retatrutide or tesamorelin. That makes it impossible to pin any one user's report on MOTS-c.
• Problems reported include redness, warmth or itching at the shot site in the first 15 to 45 minutes, and now and then nausea or headache. A 2020 forum warning described a low blood sugar type reaction after a dose. That was one report nobody could check, and it has not been seen in published studies in people. Worries about where it comes from and how pure it is come up in the same threads, next to purity certificates of unknown origin.
• Reports of no effect exist, but they are harder to find than good reports. Several dosing guide sites warn plainly that no tested dose exists for people, and that nobody has shown you will feel anything at any dose.

Sources: FDA's July 2026 evaluation of MOTS-c-related bulk drug substances, which found no FAERS side-effect reports and no published clinical studies of any kind; a forum thread on iSARMS Forums (retrieved directly) describing dosing and stacking; a 2020 warning thread on eroids.com referenced in search results but not independently retrievable for this entry; and commercial peptide-dosing and side-effect guide sites (Path to Peptides, PerfectB, FormBlends, PeptidesExplorer, Rite Aid, gethealthspan.com), which are vendor- or affiliate-adjacent and are cited here only for the dosing conventions and side-effect categories they describe, not as evidence of anything. Reddit's r/Peptides could not be retrieved for this entry, so nothing above is attributed to any specific post, and no quotation is reproduced from any of these sources.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2021
  A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c

  The gene variant that made MOTS-c famous for longevity turned out to do the opposite, and the longevity claim did not survive. Researchers pooled three large Japanese population studies covering 27,527 people. Nobody was given anything. Men carrying the weaker version of the MOTS-c gene had more type 2 diabetes, not less, and the pattern was strongest in men who did not exercise. In a separate group of 736 people aged 100 or more, the variant was no more common than in everyone else.

  Meta-analysis of 27,527 people across three Japanese cohorts (J-MICC, MEC, TMM): the reduced-function C-allele of m.1382A>C was linked to higher, not lower, prevalence of type 2 diabetes in men, especially sedentary men. In an expanded cohort of 736 centenarians, allele frequency did not differ from controls (7.7% vs 7.5%), refuting the earlier longevity hypothesis.

  PMID 33468709 Aging (Albany NY)
• Study in people2020
  Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition

  Blood and muscle tell opposite stories about MOTS-c as men age, which is a warning against reading a blood level as a health score. A hundred and four healthy men, young through old, had both measured. Nobody was given anything. In blood, older men carried about a fifth less MOTS-c than young men, and middle aged men about a tenth less. In their muscle the opposite held: older men made roughly half as much again. A snapshot like this cannot say which way cause runs.

  104 healthy men (young, middle-aged, older): circulating plasma MOTS-c was 11% and 21% lower in middle-aged and older men versus young, while skeletal muscle MOTS-c expression was about 1.5-fold higher in the older groups, an opposite-direction split between blood and tissue.

  PMID 32182209 Aging (Albany NY)
• Study in people2018
  Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction

  People with damaged blood vessel linings carried less MOTS-c in their blood, in a very small group. Forty patients having their heart arteries imaged were split by what the test showed. Twenty had poorly functioning vessel linings and twenty did not. Nobody was given anything. MOTS-c was lower in the group with the damage, and tracked how well the vessels worked. Forty people is a tiny sample, and a difference measured at one moment cannot show that low MOTS-c caused the damage.

  40 patients undergoing coronary angiography: plasma MOTS-c was lower in the 20 with endothelial dysfunction than the 20 with normal endothelial function (p=0.007) and correlated positively with coronary endothelial function.

  PMID 29242099 International Journal of Cardiology
• Study in people2018
  Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance

  Heavier boys carried less MOTS-c in their blood. Heavier girls did not. Forty obese children and teenagers in China were compared with fifty-seven of normal weight. Nobody was given anything. In boys, MOTS-c was about a fifth lower, at 465 against 584 units, and fell as weight, waist size, fasting insulin and average blood sugar rose. In girls there was no difference worth reporting. This is a snapshot of two groups, so it cannot tell you which came first.

  40 obese children/adolescents versus 57 controls in China: circulating MOTS-c was lower in obese boys (465 vs 584 ng/mL, p<.001) and correlated negatively with BMI, waist-to-hip ratio, fasting insulin, HOMA-IR and HbA1c; no significant difference in girls.

  PMID 29691953 Pediatric Diabetes
• Study in people2021
  Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes

  This study points the other way, and the MOTS-c story does not hold together. A hundred and fifty-nine adults without diabetes or heart disease had their blood measured. Nobody was given anything. Those with metabolic syndrome carried more MOTS-c, not less, and levels rose with belly fat and with fat in the liver. That is the reverse of what the diabetes and heart studies found. When studies disagree this sharply, the honest reading is that nobody knows what a blood MOTS-c level means.

  125 Chinese adults plus 34 additional Caucasian women without overt type 2 diabetes or cardiovascular disease: plasma MOTS-c was higher, not lower, in those with metabolic syndrome and rose with android and liver fat, the opposite direction from studies in diabetes and coronary disease.

  PMID 34419510 Biochimica et Biophysica Acta, General Subjects
• Study in people2021
  Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans

  Exercise did not move MOTS-c. Thirty adults were assigned to a bout of endurance exercise, a bout of weight training, or nothing at all. Humanin, a related peptide, rose after the endurance session and not after the weights. MOTS-c leaned upward but not enough to call it a real change. Neither peptide tracked how fit anyone was, by running capacity, by strength, or by the amount of mitochondrial DNA in their muscle. Thirty people is too few to settle a small effect.

  30 adults randomized to endurance exercise, resistance exercise or control: circulating humanin rose significantly after acute endurance exercise but not resistance exercise; MOTS-c showed only a non-significant trend upward, and neither peptide correlated with fitness (VO2max, strength or muscle mtDNA copy number).

  PMID 34351816 Journal of Applied Physiology
• Study in people2022
  The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and Humanin in Professional Athletes

  Professional athletes carried less MOTS-c in their blood than people who do not train, which is the opposite of what a fitness marker should do. Seventy-five athletes were compared with thirty sedentary adults. Nobody was given anything. Humanin, the related peptide, went the other way and was higher in the athletes. Among the athletes themselves, the endurance specialists had no more MOTS-c than the rest. Comparing groups who differ in many ways cannot show that training changed the level.

  30 sedentary controls versus 75 professional athletes: professional athletes had lower serum MOTS-c and higher humanin than sedentary controls; MOTS-c did not differ between high- and low/moderate-endurance athletes.

  PMID 39077591 Reviews in Cardiovascular Medicine
• Study in people2026
  A Phase 2a, randomized, double-blind, placebo-controlled study of MOTS-c in adults with prediabetes and overweight/obesity (NCT07505745)

  Nobody has results yet. This is a trial that is still recruiting, not a finding. It plans to give 120 adults with extra weight and blood sugar creeping towards diabetes a daily injection of MOTS-c or a dummy for twelve weeks, alongside lifestyle advice. Neither the participants nor the staff will know who got which. The thing being measured is how well the body handles a sugar drink at the end. Recruitment began in February 2026 and the first results are expected in 2027.

  Verified on ClinicalTrials.gov: two-arm, 1:1 randomized, quadruple-blind, placebo-controlled trial, estimated enrollment 120, daily subcutaneous injection for 12 weeks plus lifestyle counseling, primary outcome change in OGTT-derived insulin sensitivity (Matsuda Index) at week 12. Recruiting since February 2026; estimated primary completion February 2027.

  NCT07505745 ClinicalTrials.gov, Hudson Biotech
• Review of studies2015
  The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?

  An idea paper, not new data. It guessed that a MOTS-c gene variant found only in Northeast Asia might help explain why so many Japanese people reach 100. It rested on an earlier 96-person study.

  Hypothesis commentary proposing that the Northeast Asian-specific m.1382A>C mtDNA variant in MOTS-c might help explain the longevity of Japanese centenarians, based on an earlier 96-person haplogroup study; not a data paper.

  PMID 26289118 Aging Cell
• Review of studies2026
  July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee

  The FDA's official record of the July 23, 2026 advisory meeting. MOTS-c was discussed for the list of ingredients compounding pharmacies may use. It had been put forward for blood sugar problems, obesity, weak bones, hardened blood vessels, muscle and fat, and long life.

  Official FDA meeting record: MOTS-c was discussed on July 23, 2026 for possible inclusion on the 503A bulk drug substances list, nominated for insulin resistance, obesity, osteoporosis, vascular calcification, muscle/fat metabolism and longevity.

  Source U.S. FDA (Advisory Committee Calendar)
• Review of studies2026
  FDA Briefing Document for MOTS-c-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23, 2026

  The FDA's own review of MOTS-c. It found no public studies or data on people given it by any route. It found no animal studies of how it moves through the body or whether it is toxic, and no side effect reports. It advised against listing it.

  FDA reviewers found no publicly available clinical studies or human exposure data for MOTS-c-related bulk drug substances via any route, no nonclinical pharmacokinetic or toxicity studies, and no FAERS adverse event reports; concluded the criteria weigh against listing and recommended against inclusion.

  Source U.S. Food and Drug Administration, CDER
• Animal study2015
  The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

  In mice, the paper that first described MOTS-c, a 16 amino acid peptide made from mitochondrial DNA. Mice given it did not develop the blood sugar problems that come with age or a fatty diet, and did not get fat on that diet.

  Identified MOTS-c as a 16-amino-acid peptide encoded in mitochondrial 12S rRNA; treatment in mice prevented age- and diet-induced insulin resistance and diet-induced obesity via AMPK activation.

  PMID 25738459 Cell Metabolism
• Animal study2021
  MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

  In mice, MOTS-c helped young, middle-aged and old mice perform better. Started late in life, it kept them healthy for longer. In people, the same paper reports that exercise raised the body's own MOTS-c in muscle and in the blood.

  MOTS-c improved physical performance in young, middle-aged and old mice and, started late in life, increased healthspan; exercise raised endogenous MOTS-c expression in human skeletal muscle and in circulation.

  PMID 33473109 Nature Communications